ATE490465T1 - Diagnose- und prognoseverfahren von blasenkrebs. - Google Patents

Diagnose- und prognoseverfahren von blasenkrebs.

Info

Publication number
ATE490465T1
ATE490465T1 AT06719762T AT06719762T ATE490465T1 AT E490465 T1 ATE490465 T1 AT E490465T1 AT 06719762 T AT06719762 T AT 06719762T AT 06719762 T AT06719762 T AT 06719762T AT E490465 T1 ATE490465 T1 AT E490465T1
Authority
AT
Austria
Prior art keywords
bladder cancer
diagnosis
methods
present
epithelial origin
Prior art date
Application number
AT06719762T
Other languages
German (de)
English (en)
Inventor
Bruce Zetter
Adam Feldman
Scott Mcdougal
Original Assignee
Childrens Medical Center
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Gen Hospital Corp filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE490465T1 publication Critical patent/ATE490465T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06719762T 2005-01-28 2006-01-30 Diagnose- und prognoseverfahren von blasenkrebs. ATE490465T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64811005P 2005-01-28 2005-01-28
PCT/US2006/003049 WO2006081473A2 (en) 2005-01-28 2006-01-30 Methods for diagnosis and prognosis of epithelial cancers

Publications (1)

Publication Number Publication Date
ATE490465T1 true ATE490465T1 (de) 2010-12-15

Family

ID=36741098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06719762T ATE490465T1 (de) 2005-01-28 2006-01-30 Diagnose- und prognoseverfahren von blasenkrebs.

Country Status (9)

Country Link
US (7) US8685659B2 (enExample)
EP (1) EP1842065B1 (enExample)
JP (1) JP2008529008A (enExample)
CN (1) CN101268368A (enExample)
AT (1) ATE490465T1 (enExample)
AU (1) AU2006207954A1 (enExample)
CA (1) CA2595377A1 (enExample)
DE (1) DE602006018578D1 (enExample)
WO (1) WO2006081473A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
EP1512970A1 (en) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for determining the impact of a multicomponent mixture on the biological profile of a disease
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
CA2595377A1 (en) * 2005-01-28 2006-08-03 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
EP2364774A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2021113A2 (en) 2006-05-11 2009-02-11 Raindance Technologies, Inc. Microfluidic devices
EP2077912B1 (en) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
KR100767878B1 (ko) * 2006-11-07 2007-10-17 전북대학교산학협력단 간세포암 진단용 조성물, 이를 포함하는 간세포암 진단키트 및 간세포암 진단방법
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008103815A2 (en) * 2007-02-23 2008-08-28 Predictive Biosciences Corporation Clinical intervention directed diagnostic methods
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2009017475A1 (en) * 2007-07-27 2009-02-05 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
JP5120843B2 (ja) * 2008-06-04 2013-01-16 国立大学法人山梨大学 自己免疫性膵炎の検査方法及び検査試薬
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2486409A1 (en) 2009-10-09 2012-08-15 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP3392349A1 (en) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US10436797B2 (en) * 2010-06-03 2019-10-08 Idexx Laboratories, Inc. Markers for renal disease
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
EP3736281A1 (en) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US20130115599A1 (en) * 2011-11-08 2013-05-09 Medical Diagnostic Laboratories, Llc Increased cip2a expression and bladder cancer in humans
EP3495817B1 (en) 2012-02-10 2024-10-16 Bio-Rad Laboratories, Inc. Molecular diagnostic screening assay
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
US10568869B2 (en) * 2012-12-11 2020-02-25 Cornell University Methods for diagnosing and treating prostate cancer
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
NZ745263A (en) * 2016-03-02 2022-07-01 Idexx Lab Inc Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
WO2022006514A1 (en) * 2020-07-02 2022-01-06 Gopath Laboratories Llc Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer
CN112379093B (zh) * 2020-10-22 2023-06-16 上海良润生物医药科技有限公司 CST-Cathepsin复合物作为肿瘤诊断标志物的应用
CN119604763A (zh) * 2022-01-26 2025-03-11 艾德克斯实验室公司 用于区分进展性慢性肾脏疾病与稳定性慢性肾脏疾病的方法和组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
GB2236186B (en) 1989-08-22 1994-01-05 Finnigan Mat Gmbh Process and device for laser desorption of analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
NZ267842A (en) 1993-05-28 1997-09-22 Baylor College Medicine Apparatus for measuring molecular mass (by mass spectrometry) in which the sample is ionised on the sample holder and desorbed therefrom by laser pulses
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
JP2001524802A (ja) 1996-07-15 2001-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ２０ｑ１３アンプリコンからの遺伝子及びそれらの使用
JPH10262680A (ja) * 1997-03-25 1998-10-06 Kirin Brewery Co Ltd Ｒｈｏ標的タンパク質ヒトｍＤｉａおよびその遺伝子
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6642007B1 (en) 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
US20030124543A1 (en) 1999-01-15 2003-07-03 Stuart Susan G. Breast cancer marker
US6358683B1 (en) 1999-06-03 2002-03-19 The Regents Of The University Of California Blood-based assays for breast cancer
US6939714B2 (en) * 1999-06-18 2005-09-06 Biotherapies, Inc. Epithelial cell growth inhibitors
WO2001018058A2 (en) 1999-09-07 2001-03-15 Viventia Biotech Inc. Enhanced phage display library of human vh fragments and methods for producing same
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US20040142361A1 (en) * 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
KR20030031911A (ko) 2001-04-19 2003-04-23 싸이퍼젠 바이오시스템즈, 인코포레이티드 질량 분석법과 친화성 태그를 이용한 생물분자 특성화
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
JP2005500543A (ja) 2001-08-13 2005-01-06 ビヨンド ジェノミクス， インコーポレイテッド 生物学的系をプロファイリングするための方法およびシステム
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
US20030157579A1 (en) * 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
US20030199001A1 (en) 2002-04-23 2003-10-23 Pitt Aldo M. Sample preparation of biological fluids for proteomic applications
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US20070178090A1 (en) 2003-04-01 2007-08-02 Genzyme Corporation Breast endothelial cell expression patterns
CA2595377A1 (en) * 2005-01-28 2006-08-03 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
WO2009017475A1 (en) 2007-07-27 2009-02-05 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers

Also Published As

Publication number Publication date
EP1842065B1 (en) 2010-12-01
US20170023574A1 (en) 2017-01-26
AU2006207954A1 (en) 2006-08-03
CN101268368A (zh) 2008-09-17
US20180188252A1 (en) 2018-07-05
WO2006081473A8 (en) 2007-08-23
EP1842065A2 (en) 2007-10-10
JP2008529008A (ja) 2008-07-31
DE602006018578D1 (de) 2011-01-13
EP1842065A4 (en) 2008-12-31
WO2006081473A3 (en) 2007-01-18
US20080064047A1 (en) 2008-03-13
US20180120319A1 (en) 2018-05-03
US8685659B2 (en) 2014-04-01
US20090239245A1 (en) 2009-09-24
WO2006081473A2 (en) 2006-08-03
US20140106378A1 (en) 2014-04-17
CA2595377A1 (en) 2006-08-03
US20150093767A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
Pin et al. The role of proteomics in prostate cancer research: biomarker discovery and validation
ATE527544T1 (de) Vorhersage von letalität und detektion von schweren erkrankungen
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
CY1108294T1 (el) Πρωτεϊνες καρκινικων δεικτων και οι χρησεις τους
EA201400710A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
GB2467704A (en) Methods of monitoring conditions by sequence analysis
WO2009024691A3 (fr) Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal
ATE524740T1 (de) Seprase als krebsmarker
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
DK2275815T3 (da) Forbedrede immunoassay-fremgangsmåder
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
ATE501267T1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2005100999A3 (en) Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
DE602007007958D1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE412182T1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties